Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06245577
Other study ID # EVKKoeln_BioSynIRS
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 30, 2024
Est. completion date May 31, 2026

Study information

Verified date March 2024
Source Evangelisches Klinikum Köln Weyertal gGmbH
Contact Claudia L Rudroff, MD
Phone +4915123534935
Email claudia.rudroff@evk-koeln.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the pilot study is to demonstrate the safety and efficacy of a biological mesh compared to a standard synthetic mesh for the planned procedure in the above-mentioned clinical picture. Subsequently, a multicentre, randomized intervention study is planned to confirm the results and evaluate the long-term outcomes.


Description:

Obstructive defecation syndrome (ODS) is a disordered defecation process due to a protrusion and telescope-like invagination of the lower rectum (rectocele, intussusception). This is often accompanied by a dolichocolon and chronic constipation. The feeling of an obstruction in the pelvic floor leads to forced pushing behavior in order to empty the rectum. Manual manipulation (transrectal or transvaginal) may also be necessary. Repeated and unsuccessful emptying attempts are often associated with the feeling of incomplete bowel evacuation. The patients affected are deeply frustrated and their thoughts revolve around the evacuation process. Their quality of life is considerably impaired. Around 10-25% of the population are affected The clinical picture predominantly affects women and is often associated with pelvic organ prolapse (POP). In these cases, the POP is the result of pathological pushing behavior for defecation. In addition, there may be other individual etiologies, such as post-vaginal delivery, connective tissue diseases, physiological lowering of the pelvic floor with age and surgical interventions in the pelvic area, which worsen the condition]. Up to 60% of the female population suffers from POP, and a third of these suffer from bowel dysfunction in the form of constipation (33%) and/or ODS (26%). Conservative treatment options such as dietary changes, adequate fluid intake, laxative medication, physical exercise, pelvic floor training, pelvic floor biofeedback therapy with or without electro stimulation and pessary treatment are limited and do not achieve the desired long-term effect Surgery is the alternative in these cases with the aim of restoring the anatomy More than 12% of all women have to undergo surgery in the course of their lives For some time now, an interdisciplinary surgical approach has been possible in which all affected compartments can be treated in a single procedure. The current results demonstrate the safety of this approach and represent a promising option for affected patients. At the same time, the US Food and Drug Administration (FDA) issued a warning in 2008 against the use of mesh implants in reconstructive pelvic floor surgery, as serious long-term complications have sometimes been observed. With synthetic mesh, the mesh remains permanently in close proximity to the other pelvic organs and can lead to mesh infection, erosion and migration over time. These conditions can have serious consequences for individual patients and in some cases even lead to a permanent stoma. The use of synthetic mesh is restricted in the United States for both transvaginal and abdominal POP surgery due to long-term complications (erosion, migration and chronic infection of the mesh). In Germany, the use of synthetic meshes is also highly controversial and is restricted to use in POP with vaginal reconstruction for recurrent procedures. The information about serious adverse events associated with the use of synthetic mesh in reconstructive pelvic floor surgery has unsettled many patients. Women of a younger age in particular have a long life expectancy and an increased risk of adverse events due to the synthetic mesh material. Some of them still want to become pregnant after the operation. At the same time, the disease - even if it is not life-threatening - has an enormous impact on the individual's quality of life, and most of those affected still need surgery. For these patients, the use of a biological mesh appears to be a sensible alternative. The biological material carries a low risk of mesh infection, as the material allows cellular infiltration and is degraded within 12 to 18 months. There is no risk of arrosion or migration of the biological mesh due to the degradation of the material. However, the reconstruction may lose its stability after degradation of the mesh, which in some cases could lead to recurrence of the depression. This in turn could reduce the long-term success of the intervention. This is possibly the reason why the biological mesh is currently not recommended for SCP in the German guideline for pelvic floor surgery . However, there is little scientific evidence and the recommendation in the guideline is based on only two publications on this topic. At the same time, biological meshes have been used for ventral mesh rectopexy for some time with promising results. No mesh-related complications have yet been observed. As a result, the Biodesign rectopexy graft received FDA approval in the USA and CE marking in Germany in accordance with the Medical Device Directive. The data on the use of biological mesh for ventral mesh rectopexy and the wishes of the patients concerned have encouraged us to re-evaluate the issue. We are convinced that the bionet leads to the formation of scar tissue during apical fixation of the internal genitalia by means of sacrocolpopexy and in combination with resection rectopexy, which fixes the pelvic organs in place even after resorption of the mesh and prevents recurrence of descensus. In the study, the mesh is placed in the same space (between the rectum and vagina) as for the treatment of rectal prolapse/intussusception in mesh rectopexy. With this defined and standardized technique, Cook Biotech evaluates the mesh application in this pilot study as "intended use" of its approved product. Furthermore, the Ethics Committee of the University of Cologne confirms that the biological mesh is used for this pilot study within the scope of its intended purpose and in accordance with the safety and quality requirements of the European Medical Device Regulation (MDR). Thus, the study falls under ยง47 (3) of the MDR. The planned pilot study is necessary in view of the currently still negative recommendation of the German guideline, the limited data on the use of biological mesh in laparoscopic SCP and the risks associated with the use of synthetic mesh, especially in younger women, in order to find an alternative to the synthetic mesh material.


Recruitment information / eligibility

Status Recruiting
Enrollment 28
Est. completion date May 31, 2026
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - clinical diagnosis of obstructed defection syndrome - clinical diagnosis of pelvic organ prolapse pelvic organ prolapse - must be suitable for surgery Exclusion Criteria: - allergy to the components of the mesh - pregnancy

Study Design


Intervention

Device:
interdisciplinary mesh sacro colpopexy with resection rectopexy
surgical reconstruction of the middel pelvic compartment with the above mentioned meshes combined with a resection rectopexy in a simultaneous interdisciplinary procedure

Locations

Country Name City State
Germany Evangelisches Klinikum Koeln Weyertal Cologne Northrhine Westphalia

Sponsors (2)

Lead Sponsor Collaborator
Evangelisches Klinikum Köln Weyertal gGmbH University of Cologne

Country where clinical trial is conducted

Germany, 

References & Publications (7)

Ahmad M, Sileri P, Franceschilli L, Mercer-Jones M. The role of biologics in pelvic floor surgery. Colorectal Dis. 2012 Dec;14 Suppl 3:19-23. doi: 10.1111/codi.12045. — View Citation

Augusto KL, Bezerra LRPS, Murad-Regadas SM, Vasconcelos Neto JA, Vasconcelos CTM, Karbage SAL, Bilhar APM, Regadas FSP. Defecatory dysfunction and fecal incontinence in women with or without posterior vaginal wall prolapse as measured by pelvic organ prolapse quantification (POP-Q). Eur J Obstet Gynecol Reprod Biol. 2017 Jul;214:50-55. doi: 10.1016/j.ejogrb.2017.04.039. Epub 2017 Apr 26. — View Citation

Brunner M, Roth H, Gunther K, Grutzmann R, Matzel KE. Ventral rectopexy with biological mesh: short-term functional results. Int J Colorectal Dis. 2018 Apr;33(4):449-457. doi: 10.1007/s00384-018-2972-3. Epub 2018 Feb 13. — View Citation

Clemons JL, Weinstein M, Guess MK, Alperin M, Moalli P, Gregory WT, Lukacz ES, Sung VW, Chen BH, Bradley CS; AUGS Research Committee. Impact of the 2011 FDA transvaginal mesh safety update on AUGS members' use of synthetic mesh and biologic grafts in pelvic reconstructive surgery. Female Pelvic Med Reconstr Surg. 2013 Jul-Aug;19(4):191-8. doi: 10.1097/SPV.0b013e31829099c1. — View Citation

de Mattos Lourenco TR, Pergialiotis V, Durnea C, Elfituri A, Haddad JM, Betschart C, Falconi G, Doumouchtsis SK; CHORUS: An International Collaboration for Harmonising Outcomes, Research, and Standards in Urogynaecology and Women's Health. A systematic review of reported outcomes and outcome measures in randomized controlled trials on apical prolapse surgery. Int J Gynaecol Obstet. 2019 Apr;145(1):4-11. doi: 10.1002/ijgo.12766. Epub 2019 Feb 22. — View Citation

Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13. doi: 10.1097/01.sla.0000133083.54934.ae. — View Citation

Sohlberg EM, Dallas KB, Weeks BT, Elliott CS, Rogo-Gupta L. Reoperation rates for pelvic organ prolapse repairs with biologic and synthetic grafts in a large population-based cohort. Int Urogynecol J. 2020 Feb;31(2):291-301. doi: 10.1007/s00192-019-04035-3. Epub 2019 Jul 12. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary safety of the experimental internvention as measured by surgical outcome Morbidity and mortality according to the Clavien-Dindo Classification (CDC) at 12 months after surgery (maximum value) 12 months
Secondary Altomare Score for Obstruct4ed defecation syndrome (ODS) Improvement in medical condition as measured Altomare score for ODS, min/max points 0-30 point, more points indicate more severe ODS symptoms; a reduction after intervention indicatesmprovement/deterioration (-3 =better, - 6 = much better; +3=worse, +6=much worse) 12 months
Secondary Pelvic organ prolapse Quantification (POP Q) Measurement of clinical pelvic organ prolapse by the above score. min/max 0-4, more points are more symptoms. Improvement of the POP-Q is -1= good; -2 = very good; +1 =worse, +2=much worse. 12 months
Secondary Rectal Toxicity Score for bowel dysfunction Improvement in medical condition as measured rectal toxicity score for bowel dysfunction, min/max points 0-30 point, more points indicate more severe bowel dysfunction; a reduction after intervention indicates improvement/deterioration (-3 =better, - 6 = much better; +3=worse, +6=much worse) 12 months
Secondary Wexner Incontinence Score for fecal incontinence Improvement in medical condition as measured with Wexner Incontinence Score for fecal incontinence, min/max points 0-20 point, more points indicate more severe incontinence symptoms; a reduction after intervention indicates mprovement/deterioration (-3 =better, - 6 = much better; +3=worse, +6=much worse) 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05420831 - Comparison of Vaginal and Laparoscopic Apical Fixation Techniques for Pelvic Organ Prolapse Treatment N/A
Active, not recruiting NCT05422209 - The Influence of Simultaneous Posterior Colporrhaphy and Perineoplasty on the Efficiency and Safety of Mesh-augmented Sacrospinal Fixation (Apical Sling) in Advanced POP Repair. N/A
Completed NCT05493735 - Lidocaine for Pessary Check Pain Reduction Phase 3
Completed NCT06126328 - Materna Prep Study Phase II Phase 2
Recruiting NCT05542836 - EVeRLAST 2-Year Follow-Up
Recruiting NCT05918367 - Multicenter Ventral Mesh Rectopexy Registry Collaborative
Recruiting NCT04172272 - The Influence of TAP Block in the Control of Postoperative Pain After Laparotomy for Gynecological Procedures N/A
Recruiting NCT04807920 - BOTOX® at the Time of Prolapse Surgery for OAB Phase 4
Completed NCT06268782 - The Effectiveness of an Online Exercise Program on Well-being of Postpartum Women N/A
Recruiting NCT03146195 - The 3D Reconstruction Research of Pelvic Organ Prolapse Disease N/A
Recruiting NCT02919852 - Laparoscopic Retrovesical Colpopectinopexia N/A
Completed NCT02925585 - Vaginal Tactile Imaging for Pelvic Floor Prolapse
Not yet recruiting NCT02536001 - Prospective Randomized Study to Compare Results of Pelvic Organ Prolapse Repair With One Versus Two Vaginal Meshes N/A
Recruiting NCT02113969 - Conservative Management of Symptomatic Pelvic Organ Prolapse Using Vaginal Pessaries: Generation of a Standardized Management Protocol N/A
Completed NCT02383199 - Polypropylene Mesh in Prolapse Surgery N/A
Terminated NCT01673360 - Collection of Long Term Patient Outcomes Data Following Implantation of AMS Surgical Devices N/A
Completed NCT01842464 - Sacro-Spinous Ligaments Anterior Apical Anchoring N/A
Withdrawn NCT01530191 - Factors Affecting Perioperative Outcomes N/A
Completed NCT01320631 - Male Sexual Experience and Its Impact on Quality of Life Before and After Their Sexual Partners Undergo Polypropylene Mesh Augmented Pelvic Floor Reconstruction N/A
Completed NCT00581412 - Composite Graft Use in Abdominal Sacrocolpopexy Reduces Erosion Rates N/A